Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment
Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment
复制标题
DOI：
10.1002/pmic.200401287
复制
发表时间：
2005-11-01
期刊：
影响因子：
3.4
通讯作者：
Omata, M
中科院分区：
文献类型：
--
作者：
Kawakami, T;Hoshida, Y;Omata, M
比较蛋白质组学分析被用来寻找肝细胞癌（HCC）患者接受根治性射频消融治疗的血清中的特征性改变。对8例患者治疗前后的血清样品进行2-DE分析。通过聚类分析筛选出88个差异表达的蛋白质点，并基于MALDI-TOF/ TOF分析和公共数据库检索，通过MS对蛋白质进行鉴定。统计学分析表明，治疗后4种蛋白质（前载脂蛋白、α 2-HS糖蛋白、载脂蛋白A-IV前体和PRO 1708/PRO 2044，这是白蛋白的羧基末端片段）降低，7种蛋白质在治疗后升高，包括富含亮氨酸的α 2-糖蛋白和α 1-抗胰蛋白酶。这些数据有助于识别参与HCC癌变的差异表达蛋白，并为诊断和治疗工具的开发提供候选生物标志物。
Comparative proteomic analysis was used to search for characteristic alterations in the sera of hepatocellular carcinoma (HCC) patients who had undergone curative radiofrequency ablation treatment. Serum samples collected from eight patients before and after treatment were subjected to 2-DE. Eighty-eight protein spots differentially expressed with the treatment were selected by clustering analysis, and the proteins were identified by MS based on MALDI-TOF/ TOF analysis and public database searches. The statistical analysis suggested that four proteins decreased after treatment (pro-apolipoprotein, alpha 2-HS glycoprotein, apolipoprotein A-IV precursor, and PRO1708/PRO2044, which is the carboxy terminal fragment of albumin) and that seven proteins were increased after treatment, including leucine-rich alpha 2-glycoprotein and alpha 1-antitrypsin. These data facilitate the identification of differentially expressed proteins that are involved in HCC carcinogenesis and provide candidate biomarkers for the development of diagnostic and therapeutic tools.